A team of researchers has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
Although isoniazid and rifampin, two front-line TB drugs, came into use in 1952 and 1967 respectively, new TB infections still occur at the rate of roughly one per second. At any moment about a third of the existing human population is infected. Though it is mostly winactive, latent TB, active TB still kills over one million people each year, with Russia, Africa, China and Southeast Asia especially hard hit.